The Ophthalmology Therapeutics Market size in the Middle East and Africa was worth USD 3.04 billion in 2022. It is further estimated to grow at a CAGR of 8.1% and worth USD 4.48 billion by 2027.
Ophthalmology is the science associated with the treatment of eye defects and diseases. Recent advancements in genetics and stem cell biology are progressively boosting the potential for ophthalmology therapeutics.
The growing prevalence of vision impairment drives the Middle East and Africa market for Ophthalmology Therapeutics. Advancements in the field of medicine is also a key factor driving the growth of the market. The increasing geriatric population around the region and an increase in the disposable income of the people are some of the other driving factors for the Ophthalmology Therapeutics Market.
However, limited awareness about the diseases associated with ophthalmology is the key restraint for the market's growth. Uncertain reimbursement policies and stringent regulatory frameworks are some of the other factors restraining the market's growth.
This research report on the MEA Ophthalmology Therapeutics Market has been segmented and sub-segmented into the following categories:
By Indication:
By End User:
By Country:
Based on end-user, the Hospital segment accounts for the largest share of the market with a percentage share of approximately XX%. At the same time, Diagnostics Centres are the fastest-growing segment with a CAGR of XX%.
Geographically, Middle-East is the largest market for Ophthalmology Therapeutics due to the people's high disposable income. Africa is estimated to be the fastest-growing region with a CAGR of xx% during the forecast period.
Prominent companies leading the MEA Ophthalmology Therapeutics Market are Pfizer Inc., Allergan Inc., Alcon Inc., Merck & co. Inc., Roche Valeant, Regeneron, Santen, Bayer, Senju, Lpath, and Eye Gate Pharmaceuticals.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Indication
5.1.1 Glaucoma
5.1.2 Dry Eye Syndrome
5.1.3 Diabetic Retinopathy
5.1.4 Retinal Vein Occlusion
5.1.5 Age-Related Macular Degeneration (AMD)
5.1.6 Macular Edema
5.1.7 Allergic Conjunctivitis
5.2 By End User
5.2.1 Hospitals
5.2.2 Eye Clinics
5.2.3 Diagnostic Centers
5.2.4 Patients
6. Geographical Analysis
6.1 Introduction
6.2 Middle-East
6.3 Africa
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 Allergan, Inc.
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.2 Merck & Co Inc
9.3 Pfizer
9.4 Roche
9.5 Novartis (Alcon)
9.6 Valeant
9.7 Regeneron
9.8 Santen
9.9 Bayer
9.10 Senju
9.11 Lpath
9.12 Eye Gate Pharmaceuticals
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Market Outlook & Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
